Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Rating of “Buy” from Brokerages

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have earned an average rating of “Buy” from the twelve brokerages that are currently covering the stock, Marketbeat.com reports. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $56.27.

Several equities research analysts have recently weighed in on MIRM shares. HC Wainwright reissued a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a research note on Friday, July 26th. Robert W. Baird boosted their price objective on Mirum Pharmaceuticals from $39.00 to $44.00 and gave the stock an “outperform” rating in a report on Thursday, August 8th. Cantor Fitzgerald upped their price objective on shares of Mirum Pharmaceuticals from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. Baird R W raised shares of Mirum Pharmaceuticals to a “strong-buy” rating in a research report on Monday, June 17th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $48.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday, June 17th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Quest Partners LLC boosted its stake in shares of Mirum Pharmaceuticals by 7,513.3% during the 2nd quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock valued at $39,000 after buying an additional 1,127 shares during the period. Amalgamated Bank boosted its position in Mirum Pharmaceuticals by 60.8% during the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after purchasing an additional 513 shares during the last quarter. StepStone Group LP purchased a new position in Mirum Pharmaceuticals in the fourth quarter valued at about $135,000. ProShare Advisors LLC purchased a new position in Mirum Pharmaceuticals in the second quarter valued at about $213,000. Finally, NEOS Investment Management LLC acquired a new position in Mirum Pharmaceuticals in the 4th quarter worth about $220,000.

Mirum Pharmaceuticals Stock Down 1.3 %

MIRM opened at $38.75 on Tuesday. The stock’s 50 day moving average price is $40.75 and its 200 day moving average price is $32.92. The company has a debt-to-equity ratio of 1.34, a current ratio of 3.28 and a quick ratio of 3.09. The stock has a market cap of $1.83 billion, a P/E ratio of -10.44 and a beta of 1.14. Mirum Pharmaceuticals has a 12 month low of $23.14 and a 12 month high of $45.23.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05). Mirum Pharmaceuticals had a negative return on equity of 43.47% and a negative net margin of 40.34%. The company had revenue of $77.90 million for the quarter, compared to the consensus estimate of $75.03 million. During the same quarter last year, the firm posted ($0.92) earnings per share. The firm’s quarterly revenue was up 107.7% compared to the same quarter last year. As a group, research analysts predict that Mirum Pharmaceuticals will post -1.75 earnings per share for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.